Concurrent chemoradiotherapy in non-small cell lung cancer (Q24245635)

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

A new international staging system for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

Split-course irradiation compared to split-course irradiation plus hydroxyurea in inoperable bronchogenic carcinoma--a randomized study of 53 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Unresectable squamous cell carcinoma of the lung and its management by combined bleomycin and radiotherapy.A clinical study of the enhanced results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

A randomized prospective study of radiation versus radiation plus ACNU in inoperable non-small cell carcinoma of the lung. Japan Radiation-ACNU Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002140.PUB2

7 January 2021

10.1002/14651858.CD002140.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

15495029

1 reference

Consolidated OpenCitations Corpus – April 2017